Strategic partnership Liomont recently expanded collaboration with Moderna Therapeutics for mRNA manufacturing via technology transfer, signaling a strong openness to strategic partnerships with global players. This creates opportunities to propose joint development programs, supply contracts, or co-investment in new manufacturing capabilities.

Scale and capacity With a modern plant capable of producing over 120 million units annually and a workforce of 1,700+, Liomont offers scalable manufacturing capacity to support high-volume contracts, contract manufacturing, and rapid scale-up for new product launches.

Market positioning As a leading Mexican pharmaceutical company serving both prescription and OTC markets, Liomont presents a ready market for quality, affordable medicines, presenting cross-sell opportunities for generic lines, line extensions, and regional distribution agreements.

Digital and data readiness Utilizing tools like SAP, Microsoft Azure, Power BI and SQL Server indicates mature data and ERP capabilities, suggesting opportunities to offer digital supply chain solutions, demand planning services, or analytics partnerships to optimize manufacturing and distribution.

Public funding and growth Participation in a growing life sciences investment cycle in Mexico and a revenue range in the upper mid-market positions Liomont as a target for equity investments, joint ventures, or preferred supplier arrangements with multinational pharma players seeking regional manufacturing and market access.